TecPioneer - Japan: Panel Interview of ONcology practices with Emergent Experience of Teclistamab in the Real World (Japan)

TecPioneer - Japan: Panel Interview of ONcology practices with Emergent Experience of Teclistamab in the Real World (Japan) - TecPioneer - Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059681

Enrollment

Registered

2025-12-01

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.18+ years of age at the time of the study participation. 2.Board certified in oncology or hematology and currently practicing medicine in Japan. 3.Has prescribed and treated at least one (1) patient with teclistamab for relapsed or refractory multiple myeloma in the real-world setting. 4.Japanese-language proficient. 5.Provides verbal consent to all terms of research participation. 6.Willing and able to participate in a recorded web-based video conferencing interview.

Exclusion criteria

Exclusion criteria: Any individual who does not meet all inclusion criteria.

Design outcomes

Primary

Measure	Time frame
As this study is qualitative in nature, typical outcome measures will not be collected for quantitative analysis. Key themes will include: 1) Teclistamab treatment strategies and administration models (patient selection, dosing considerations, etc.) 2) Participants' current practices in anticipating, monitoring, and managing AEs (e.g., CRS, neurotoxicity, infection) 3) Administration models for teclistamab, including future recommendations.	—

Measure

Time frame

As this study is qualitative in nature, typical outcome measures will not be collected for quantitative analysis. Key themes will include: 1) Teclistamab treatment strategies and administration models (patient selection, dosing considerations, etc.) 2) Participants' current practices in anticipating, monitoring, and managing AEs (e.g., CRS, neurotoxicity, infection) 3) Administration models for teclistamab, including future recommendations.

—

Countries

Japan

Contacts

Public ContactTetsuri Suzuki

INTAGE Healthcare Inc. Value & Access Department

suzuki.49352@intage.com03-5294-8393

Outcome results